![Pharmaceutical sciences / Health / Astellas Pharma / Methicillin-resistant Staphylococcus aureus / Skin and skin structure infection / Food and Drug Administration / Antibiotics / Telavancin / Medicine Pharmaceutical sciences / Health / Astellas Pharma / Methicillin-resistant Staphylococcus aureus / Skin and skin structure infection / Food and Drug Administration / Antibiotics / Telavancin / Medicine](https://www.pdfsearch.io/img/d688420f99783f2a63b417017ea57abd.jpg)
| Document Date: 2008-09-18 20:34:44 Open Document File Size: 38,63 KBShare Result on Facebook
City SOUTH SAN FRANCISCO / Tokyo / DEERFIELD / / Company Astellas Astellas Pharma US Inc. / Theravance Inc. / Astellas Pharma US Inc. / Astellas Pharma Inc. / GlaxoSmithKline plc / TD / / Country Japan / United States / Canada / / Event Conference Call / Business Partnership / FDA Phase / / IndustryTerm biopharmaceutical / manufacturing practices / manufacturing / pharmaceutical products / pharmaceutical / / MedicalCondition bacterial infections / gastrointestinal motility dysfunction / hospital-acquired pneumonia / serious Gram-positive bacterial infections / skin and skin structure infections ( csssis ) / MRSA infections / serious Gram-positive infections / respiratory disease / / Organization U.S. Food and Drug Administration / American Medical Association / FDA / Centers for Disease Control and Prevention / / Person Rick E Winningham / / / Position Chief Executive Officer / global category leader / / Product Telavancin / / ProvinceOrState Illinois / California / / PublishedMedium the Journal of the American Medical Association / / Technology drug discovery / anti-infectives / / URL www.theravance.com / www.astellas.com/us / /
SocialTag |